CLLS52

Cellectis S.A. · Phase 1 active Biologic

At a glance

Generic name	CLLS52
Also known as	Alemtuzumab
Sponsor	Cellectis S.A.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) (PHASE1, PHASE2)
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (PHASE1, PHASE2)
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CLLS52 CI brief — competitive landscape report
CLLS52 updates RSS · CI watch RSS
Cellectis S.A. portfolio CI